Revolution Medicines (Revolution Medicines) Cash-to-Debt : 21.07 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Revolution Medicines's cash to debt ratio for the quarter that ended in Dec. 2023 was 21.07.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Revolution Medicines could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Revolution Medicines's Cash-to-Debt or its related term are showing as below:

RVMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.66 Med: 21.07 Max: No Debt
Current: 21.07

During the past 7 years, Revolution Medicines's highest Cash to Debt Ratio was No Debt. The lowest was 8.66. And the median was 21.07.

RVMD's Cash-to-Debt is ranked better than
65.54% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs RVMD: 21.07

Revolution Medicines Cash-to-Debt Historical Data

The historical data trend for Revolution Medicines's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Revolution Medicines Cash-to-Debt Chart

Revolution Medicines Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

13.49

8.66

10.05

21.07

Revolution Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															10.05	14.31	14.38	12.94	21.07

Competitive Comparison of Revolution Medicines's Cash-to-Debt

For the Biotechnology subindustry, Revolution Medicines's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revolution Medicines's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Cash-to-Debt falls into.

Revolution Medicines Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Revolution Medicines's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1852.955	/	(7.369	+	80.575)
	=	21.07

Revolution Medicines's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1852.955	/	(7.369	+	80.575)
	=	21.07

Revolution Medicines (NAS:RVMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Revolution Medicines Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Revolution Medicines (Revolution Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

42Z:Germany

Address

700 Saginaw Drive, Redwood City, CA, USA, 94063

Website

https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Executives

Stephen Michael Kelsey	officer: See Remarks	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Jeff Cislini	officer: General Counsel	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark A Goldsmith	director, officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Margaret A Horn	officer: See Remarks	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders	officer: Chief Financial Officer	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang	officer: See Remarks	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder	director	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Sushil Patel	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson	director, 10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139